Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Sandoz’ Saynor Insists On Value Of ‘Pure Play’ Approach
CEO Also Discusses US Leadership Change And Importance Of Japan
Jan 28 2021
•
By
David Wallace
Saynor says Sandoz’ ‘pure play’ strategy sets it apart from its peers • Source: Sandoz
More from Strategy
More from Business